ETH Zurich adopts VisEn's fluorescence molecular
tomography system for molecular imaging
30 August 2006
Woburn, Mass., USA. Eidgenössische Technische Hochschule
Zürich (ETHZ — The Swiss Federal Institute of Technology Zurich) has adopted
VisEn's portfolio of in vivo fluorescence probes and fluorescence molecular
tomography (FMT) imaging system, for its molecular imaging programs.
VisEn's fluorescence imaging technologies and products are designed to
provide robust and accurate imaging performance in identifying,
characterizing and quantifying a range of biological phenomena in vivo,
including known molecular activities underlying disease states such as
cancer, inflammation, cardiovascular disease and bone disease.
By imaging these disease-related biologic activities in vivo, VisEn's
technology platforms enable expanded areas of research and more efficient
drug development. They are also designed for expansion into biologic imaging
in the emerging field of personalized medicine. VisEn Medical also
announced that Dr. Markus Rudin, Professor of Molecular Imaging and
Functional Pharmacology at ETHZ has joined its Scientific Advisory Board.
Kirtland G. Poss, President and Chief Executive Officer of VisEn said, "Dr.
Rudin's deep scientific heritage and guiding role in molecular imaging has
been one of the pioneering forces of the whole field, first in drug
development with Novartis, and now in industry-leading research with ETH.
Our work with Dr. Rudin over the years has been an important factor in
shaping our technology platforms to date, and his further role as an advisor
to VisEn will help drive our technologies and the field of molecular imaging
forward. We are honoured by his participation with VisEn and see this as yet
another key foundation for our company's leadership."
Dr. Rudin added, "Real-time imaging of biologic and molecular
processes in vivo is playing an increasingly central role in
basic research and drug development today. VisEn's FMT imaging
system and probe platforms were developed in close collaboration
with leading researchers, pharmaceutical companies and
clinicians. The result is an unprecedented level of
biologically-relevant data specificity and quantification, that
together, will propel this area from basic research and
pre-clinical imaging studies today and pave the way to the
future of personalized medicine. I look forward to collaborating
even more deeply with VisEn's Scientific Advisory Board and
management on the future of this promising area of research."